City of Hope

City of Hope Appoints Alan H. Bryce, M.D., as Chief Clinical Officer at City of Hope Cancer Center Phoenix and Professor of Molecular Medicine at TGen

Retrieved on: 
Tuesday, November 7, 2023
Oncology, Health, Genetics, Clinical Trials, Research, Science, Translational Genomics Research Institute, Clinical Genitourinary Cancer, City of Hope, Therapy, Bryce, D.O, Prostate cancer, Internal medicine, Multimedia, National Cancer Institute, Hematology, City, Genomics, Division, Clinical trial, Medicine, Molecular medicine, Melanoma, Cancer, Patient, Mayo Clinic, Dietary supplement, Pharmaceutical industry, Hope, Phoenix

City of Hope, one of the largest cancer research and treatment organizations in the United States, today announced the appointment of Alan H. Bryce , M.D., as the chief clinical officer at City of Hope Cancer Center Phoenix and professor of molecular medicine at Translational Genomics Research Institute (TGen), part of City of Hope.

Key Points: 
  • City of Hope, one of the largest cancer research and treatment organizations in the United States, today announced the appointment of Alan H. Bryce , M.D., as the chief clinical officer at City of Hope Cancer Center Phoenix and professor of molecular medicine at Translational Genomics Research Institute (TGen), part of City of Hope.
  • View the full release here: https://www.businesswire.com/news/home/20231107722066/en/
    City of Hope appoints Alan H. Bryce, M.D., as chief clinical officer at City of Hope Cancer Center Phoenix and professor of molecular medicine at TGen.
  • (Photo: City of Hope)
    “We are excited to welcome Dr. Bryce to City of Hope Cancer Center Phoenix and look forward to his leadership in delivering advanced cancer care to Arizona patients,” said Kevin Tulipana, D.O., M.S., president of City of Hope Cancer Center Phoenix.
  • “I am delighted to welcome Dr. Bryce to City of Hope and TGen,” said Jeffrey M. Trent, Ph.D., TGen president and research director.

TScan Therapeutics Announces Upcoming Presentation at the 65th American Society of Hematology Annual Meeting and Exposition

Retrieved on: 
Thursday, November 2, 2023
City of Hope, TCR, Society, ASH, City, Poster, KOL, Exposition, Cancer, Therapy, Patient, American Society for Investigative Pathology, Haematopoietic system, Pharmaceutical industry, Hematology

Title: Initial Results of a Phase 1 Trial of TSC-100 and TSC-101, Engineered T Cell Therapies That Target Minor Histocompatibility Antigens to Prevent Relapse after Allogeneic Hematopoietic Cell Transplantation

Key Points: 
  • Title: Initial Results of a Phase 1 Trial of TSC-100 and TSC-101, Engineered T Cell Therapies That Target Minor Histocompatibility Antigens to Prevent Relapse after Allogeneic Hematopoietic Cell Transplantation
    Session Name: 704.
  • Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster I
    The Company will host a virtual KOL event featuring Monzr M. Al Malki, M.D., on Monday, December 11, 2023, at 8:00 a.m.
  • Dr. Al Malki is an associate professor in the Department of Hematology & Hematopoietic Cell Transplantation, director of the unrelated donor bone marrow transplant and haploidentical transplant programs at City of Hope.
  • A copy of the presentation materials will be added to the “ Events and Presentations ” section of the Company’s Investor Relations website at ir.tscan.com once presentations have concluded.

City of Hope Vice Physician-in-Chief Edward S. Kim, M.D., M.B.A, Recognized as a Top Diversity Leader in U.S. Healthcare

Retrieved on: 
Monday, November 6, 2023
Oncology, Professional Services, DEI (Diversity, Equity and Inclusion), Health, Clinical Trials, Research, Science, Faculty, Policy, Modern Healthcare, Friends, American Society of Clinical Oncology, City of Hope, Cancer Prevention Research, Lung cancer, Physician, Friends of Cancer Research, Head, State, Organization, The Lancet, Journal, Society, Multimedia, Quality of life, City, Lung, Clinical trial, Diversity, Journal of Clinical Oncology, Cancer Discovery (journal), Patient, ASCO, National Integration Party (Costa Rica), Nature Medicine, Pharmaceutical industry, Hospital, Nursing, Medical imaging, Hope, Cancer, Lancet

City of Hope, one of the largest cancer research and treatment organizations in the United States, announced today that Vice Physician-in-Chief Edward S. Kim , M.D., M.B.A., has been named a 2023 Modern Healthcare Top Diversity Leader .

Key Points: 
  • City of Hope, one of the largest cancer research and treatment organizations in the United States, announced today that Vice Physician-in-Chief Edward S. Kim , M.D., M.B.A., has been named a 2023 Modern Healthcare Top Diversity Leader .
  • The prestigious honor recognizes diverse health care executives and organizations influencing policy and care delivery across the country.
  • This is the second time Kim — a renowned lung cancer expert and physician-executive — has earned this recognition.
  • “Ed is deeply committed to ensuring that everyone we serve has equitable access to advanced cancer care,” said Annette Walker, president, City of Hope Orange County.

EQS-News: Defence Therapeutics Inc.: DEFENCE’S NOVEL ACCUTOXTM CONTINUES TO SURPRISE ON RESULTS AGAINST CANCER

Retrieved on: 
Thursday, October 26, 2023
FDA, IND, City of Hope, Nivolumab, Chitosan, Beckman Research Institute, Injection, News, Defense, CDMO, Nanoparticle, BMS, City, Lymphoma, Antibody, City of Hope National Medical Center, Animal, Molecular medicine, Melanoma, Cancer, Lung cancer, Therapy, Relatlimab, Endoplasmic reticulum, Breast, Patient, Peptide, DNA, Pharmaceutical industry, Vaccine

Vancouver, BC, Canada, October 17th, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that the excitement around AccuTOXTM against cancer continues to develop and expand its applications.

Key Points: 
  • Vancouver, BC, Canada, October 17th, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that the excitement around AccuTOXTM against cancer continues to develop and expand its applications.
  • The AccuTOXTM molecule can eradicate cancer cells via different mechanisms including the initiation of immunogenic cells death, endoplasmic reticulum stress and by causing direct damages to DNA.
  • AccuTOXTM triggers cancer tumor regression, Defence also recently demonstrated that encapsulated AccuTOXTM with chitosan nanoparticles triggers complete tumor regression in animals with pre-established solid lymphoma.
  • Further development and expanding applications on Defence’s leading AccuTOXTM therapeutic is ongoing and further news to be released upon results.

New Study from AccessHope Affirms Cancer Subspecialist Reviews Improve Pancreatic Cancer Treatment Paths

Retrieved on: 
Tuesday, October 24, 2023
Neoplasm, Research, Cancer, City of Hope, Pancreas, Physician, Acupuncture & Electro-Therapeutics Research, Mortality, Prevalence, Dana–Farber Cancer Institute, City, Disease, LOS, Pancreatic cancer, Oncology, Therapy, Patient, Diagnosis, Pharmaceutical industry, Medical imaging, Hope

Pancreatic cancer is the third leading cause of cancer mortality in the U.S. but accounts for just 3% of cancer cases.

Key Points: 
  • Pancreatic cancer is the third leading cause of cancer mortality in the U.S. but accounts for just 3% of cancer cases.
  • Approximately 80-90% of patients with pancreatic cancer have unresectable tumors, meaning surgery is not a viable treatment option.
  • Determining the correct stage of disease at diagnosis and ensuring timely and coordinated multidisciplinary care is critical to attaining optimal outcomes for patients with pancreatic cancer.
  • The study on AccessHope's collaboration with NCI-Designated Comprehensive Cancer Centers evaluated data from 94 pancreatic cancer cases between August 2019 and December 2022.

City of Hope's Music, Film and Entertainment Industry group and Lyor Cohen raise over $4.3 million to improve health equity in cancer care

Retrieved on: 
Thursday, October 19, 2023
Oncology, General Health, Health, Music, Hospitals, General Entertainment, Celebrity, Entertainment, Science, Elektra Records, DJ Jazzy Jeff, LL Cool J, Diabetes, Irell & Manella Graduate School of Biological Sciences, Spirit of Life, Health equity, Partnership, Public Enemy, Kid Capri, Prognosis, Onyx, Universal Music Publishing Group, Fear, Marketing, Magic, NORE, Cancer, Patient, Jewish National Fund Tree of Life Award, Helen, Monte, Pacific Design Center, Research, City, EPMD, Pacific Ocean, Getty, Nursing, Nice, Black, City of Hope, Family, MC Serch, Multimedia, Nightclub, Pharmaceutical industry, Video game, Dietary supplement, Vaccine, Dominoes, Hope, Spirit

Led by Cohen, MFEI raised over $4.3 million to benefit City of Hope's efforts to address the challenges underserved populations face in obtaining access to quality cancer care.

Key Points: 
  • Led by Cohen, MFEI raised over $4.3 million to benefit City of Hope's efforts to address the challenges underserved populations face in obtaining access to quality cancer care.
  • Led by Cohen, MFEI raised over $4.3 million to benefit City of Hope's efforts to address the challenges underserved populations face in obtaining access to quality cancer care.
  • The dollars raised are a significant achievement during a milestone year as City of Hope celebrates 50 years of philanthropic partnership with MFEI.
  • “Cancer doesn’t take a break and neither does City of Hope and its Music, Film and Entertainment Industry group,” Lamberg said.

H. Jack West, MD, Renowned Oncologist & Lung Cancer Expert, Joins Summit Therapeutics as Vice President of Clinical Development

Retrieved on: 
Thursday, October 19, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Knowledge, Massachusetts General Hospital, SMMT, Harvard Medical School, Publishing, City of Hope, Medical director, Lung cancer, GRACE, Drug, Summit, Quality of life, City, Global resources dividend, Providence Health & Services, Medscape, University, Therapy, Patient, Hospital, UpToDate, Associate, Pharmaceutical industry, Medical device, Nursing, MD

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Howard “Jack” West, MD, has joined Summit Therapeutics as Vice President of Clinical Development focused on lung cancer.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Howard “Jack” West, MD, has joined Summit Therapeutics as Vice President of Clinical Development focused on lung cancer.
  • West brings a wealth of experience, and his knowledge in treating lung cancer patients is unrivaled,” stated Dr. Maky Zanganeh, Chief Executive Officer and President of the Company.
  • We are thrilled to welcome Jack to our team.”
    Dr. West joins Summit from City of Hope, one of the nation’s leading cancer treatment and research centers.
  • As a practicing physician, Dr. West has been a principal investigator in over 20 clinical trials in lung cancer.

Fortress Biotech Subsidiary Helocyte Announces Option Agreement with City of Hope for Exclusive Worldwide Rights to use a Novel Bispecific CMV/HIV CAR T Cell Therapy (optionally in combination with Triplex) for the Treatment of Adults Living with HIV-1

Retrieved on: 
Monday, October 16, 2023
Patent, Investigational New Drug, Engineering, Food, California Institute for Regenerative Medicine, Viral load, Research, Drug resistance, Trial of the century, Cytomegalovirus, Criticism of the Food and Drug Administration, Risk, Gene, HIV-1, Aaron, Safety, University, HIV, HCT, Survival, ART, City, Vaccination, City of Hope, Non-Hodgkin lymphoma, Regenerative medicine, Bone marrow, Virus, CAR, Leukemia, Fortress Biotech, DSM-IV codes, 2004 California Proposition 71, San Diego, CIRM, Division of Acquired Immunodeficiency Syndrome, Patient, CMV, Vaccine, Triplex, Hope

MIAMI, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Helocyte, Inc. (“Helocyte”), a subsidiary company of Fortress Biotech, Inc. (“Fortress”) (Nasdaq: FBIO), today announced that it executed an exclusive option agreement with City of Hope for patent rights to use Triplex, a cytomegalovirus vaccine, in combination with cytomegalovirus (“CMV”)-specific, Anti-Human Immunodeficiency Virus (“HIV”) Chimeric Antigen Receptor (“CAR”) (collectively, CMV/HIV-CAR) T Cells for the treatment of adults living with HIV. Triplex was initially developed by City of Hope, one of the largest cancer research and treatment organizations in the United States, and exclusively licensed to Helocyte in 2015.

Key Points: 
  • Triplex was initially developed by City of Hope , one of the largest cancer research and treatment organizations in the United States, and exclusively licensed to Helocyte in 2015.
  • Additionally, the California Institute for Regenerative Medicine (“CIRM”) recently awarded a $11.3 million grant to City of Hope to fund a Phase 1 clinical trial.
  • The trial will initially enroll at City of Hope and University of California at San Diego.
  • The study illustrated the potential long-term durability of the combination therapy, which induced therapeutic immune cells to take hold in bone marrow.

City of Hope and TGen Research Reveals What Potentially Causes a Leukemia to Become More Aggressive

Retrieved on: 
Wednesday, October 11, 2023
Research, Genetics, Health Technology, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Mining, Multimedia, HIV disease progression rates, Food, Division, Food and Drug Administration Amendments Act of 2007, Genome, RNA, CML, Identity provider (SAML), Carter, Heart, AML, Disease, Patient, City, Leukemia Research, City of Hope, Acute leukemia, Bone marrow, Gene, Ruxolitinib, Robert, Clinical trial, Myeloproliferative neoplasm, Mouse, Translational Genomics Research Institute, Pancreatic serous cystadenoma, Nature Communications, BP, SAML, Pharmaceutical industry, Vaccine, Medical imaging, Hope, Leukemia

View the full release here: https://www.businesswire.com/news/home/20231011243325/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231011243325/en/
    City of Hope's Guido Marcucci, M.D., and team conducted the research.
  • They found that adding miR-142 prevented CML transformation and some mice with BP CML were even cured of their disease.
  • Another track funds a diagnostic project at TGen using genomic sequencing to uncover strategies to pinpoint and prevent disease progression.
  • Thanks to the Carter Altman Foundation, the TGen team is viewing all 3 billion letters of a patient’s genome in two days or less.

John D. Carpten, Ph.D., City of Hope’s Chief Scientific Officer, Elected to Prestigious National Academy of Medicine

Retrieved on: 
Monday, October 9, 2023
Science, DEI (Diversity, Equity and Inclusion), Biotechnology, Research, Oncology, Health, Professional Services, Genetics, Morgan, Incidence, National Academy of Medicine, Multimedia, Beckman Research Institute, Medicine, City of Hope National Medical Center, Irell & Manella, Biology, Breast cancer, NAM, Multiple myeloma, Mortality, Irell & Manella Graduate School of Biological Sciences, Cancer, National academy, Diabetes, Patient, City, Workforce, City of Hope, Policy, Colorectal cancer, Cell biology, African Americans, Health equity, Prostate cancer, Genomics, Deana, National Cancer Institute, Dietary supplement, Vaccine, Management, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20231009647781/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231009647781/en/
    John D. Carpten, Ph.D., chief scientific officer at City of Hope, was presented with one of the highest honors in health and medicine on Oct. 9, 2023, when he was elected to the National Academy of Medicine.
  • Carpten has numerous national leadership roles and is the first African American to chair the National Cancer Institute’s National Cancer Advisory Committee.
  • Carpten is director of the National Cancer Institute-designated City of Hope comprehensive cancer center and director of Beckman Research Institute of City of Hope.
  • “I am deeply humbled to be elected a member of the National Academy of Medicine.